Research Article

Negative Feedback of the cAMP/PKA Pathway Regulates the Effects of Endoplasmic Reticulum Stress-Induced NLRP3 Inflammasome Activation on Type II Alveolar Epithelial Cell Pyroptosis as a Novel Mechanism of BLM-Induced Pulmonary Fibrosis

Qiaohui Hong, Yue Zhang, Weixian Lin, Wei Wang, Yafei Yuan, Jiajia Lin, Zhanzhan Xie, Xu Li, and Ying Meng

Departments of Respiratory and Critical Care Medicine, Chronic Airways Diseases Laboratory, Nanfang Hospital, Southern Medical University, Guangzhou, China

Correspondence should be addressed to Xu Li; mylx99@163.com and Ying Meng; nfyymengy@163.com

Received 18 May 2022; Accepted 23 June 2022; Published 18 August 2022

Academic Editor: Fu Wang

Copyright © 2022 Qiaohui Hong et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Endoplasmic reticulum stress (ER stress) contributes to the development of pulmonary fibrosis, especially in type II alveolar epithelial cells (AECs) apoptosis, and a mechanism refers to the progression of pulmonary fibrosis [1–3]. However, accumulating evidence showed that ER stress stimulates NLRP3 inflammasome activation which linked to many diseases, such as cardiovascular disease [4], diabetes mellitus [5, 6], and steatohepatitis [7]. Indeed, previous investigations have also confirmed that NLRP3 inflammasome activation may contribute to disease progression in pulmonary fibrosis [8–13]. Therefore, whether ER stress-induced NLRP3 inflammasome activation promotes type II AECs pyroptosis and exacerbates pulmonary fibrosis needs to be established.

1. Introduction

Endoplasmic reticulum stress (ER stress) promotes type II alveolar epithelial cells (AECs) apoptosis, and a mechanism refers to the progression of pulmonary fibrosis [1–3]. However, accumulating evidence showed that ER stress stimulates NLRP3 inflammasome activation which linked to many diseases, such as cardiovascular disease [4], diabetes mellitus [5, 6], and steatohepatitis [7]. Indeed, previous investigations have also confirmed that NLRP3 inflammasome activation may contribute to disease progression in pulmonary fibrosis [8–13]. Therefore, whether ER stress-induced NLRP3 inflammasome activation promotes type II AECs pyroptosis and exacerbates pulmonary fibrosis needs to be established.

Cyclic adenosine monophosphate (cAMP) is a well-characterized second messenger that activates phosphorylation of protein kinase A (PKA) and further regulates cell signaling pathways [14]. In 2012, Lee et al. reported that Ca²⁺ in macrophages inhibited the expression of intracellular cAMP, resulting in NLRP3 inflammasome activation via
calcium-sensing receptors [15]. Subsequently, numerous studies have confirmed that cAMP/PKA activation inhibited NLRP3 inflammasome activation [16–20]. Interestingly, ER stress may promote cAMP/PKA activation [21, 22]. Thus, we speculated that the negative feedback of the cAMP/PKA pathway regulated ER stress-induced NLRP3 inflammasome activation and pyroptosis in type II AECs which may act as a novel mechanism of pulmonary fibrosis.

In this study, we explored whether ER stress-induced NLRP3 inflammasome activation promotes type II AECs pyroptosis in a mouse model of bleomycin- (BLM-) induced pulmonary fibrosis. Furthermore, we also investigated whether ER stress upregulated cAMP/PKA pathway and whether upregulation of the cAMP/PKA pathway suppressed ER stress-induced NLRP3 inflammasome activation and pyroptosis in type II AECs which alleviated pulmonary fibrosis.

2. Methods

2.1. Ethics Statement. Animal experiments were approved by ethics committee of Nanfang hospital and conform to the relevant norms of animal ethics.

2.2. Animal Experiments. Male C57/BL mice (aged 5–8 weeks) were obtained from animal breeding facility of Southern Medical University. Mice were divided into two groups with 10 mice per group: the BLM group and the control group. Mice in the BLM group were given 5 mg/kg bleomycin through tracheal administration under anesthesia; the control group was given the equivalent amount sterile saline in the same way. All mice were sacrificed after 28 days.

2.3. Histological and Immunohistochemical Analyses. Immunohistochemical staining of paraffin-embedded lung sections (4 μm) was performed with primary antibodies against Grp78, Grp94, CHOP, NLRP3, IL-1β, ASC, GSDMD, and PKA (1: 200, Proteintech, China). Immunoreactivity was visualized using a commercial HRP-based method (GTVision TM Detection System/Mo&Rb, Denmark).

2.4. Immunofluorescence Histochemistry. Immunofluorescent staining of lung sections (4 μm) was performed by incubation overnight in low temperature with combinations of detective primary antibodies. After being hatched with different species and different wavelengths of secondary antibodies, images were visualized under fluorescence microscope.

2.5. Immunocytochemistry. Cells cultured on glass coverslips were fixed with paraformaldehyde, ruptured membrane with Triton X-100 and sealed with FBS (fetal bovine serum), and then hatched overnight at 4°C in a moist chamber with the primary antibodies. PBST was used to clean the primary antibody and hatch the fluorescent secondary antibody. Finally, images were observed by fluorescence microscope within 48 hours.

2.6. LDH Release Assay. LDH was released following cell death because of disruption of the plasma damage. Cell viability was assessed by the concentration of LDH release which was detected by LDH cytotoxicity assay detection kit (Beyotime, China).

2.7. CCK8 Assay. Cell viability was evaluated by CCK8 assay (FUDE, China).

2.8. cAMP Measurement. The concentration of cAMP was determined using an ELISA kit (SAB, America).

2.9. siRNA-Mediated Silencing of NLRP3. A549 cells were incubated into 6- or 96-well plates and transfected with a NLRP3 siRNA (siNLRP3 sense: 5’CCAAGAAUCCAAGU GUAATT 3’; siNLRP3 antisense: UUACACUGUGGAU CUUGGCT) or a negative control using Lipofectamine 3000 (Invitrogen, America). Transfection efficiency was evaluated by Western blot and qPCR analyses.

2.10. Western Blot Analysis. Western blot was performed in a standardized procedure. PVDF membranes were incubated with specific antibodies against Grp94, CHOP, NLRP3, IL-1β, caspase-1, GSDMD, PKA, cleaved IL1β (1: 1,000, Proteintech, China), cleaved IL1β (1:10,00, Bioss, China), and GADPH (1:10,000, FUDE, China).

2.11. Real-Time Quantitative-PCR Analysis. Total RNA was extracted in a standardized procedure with the following normalized detection methods. The expression of mRNA was normalized against GADPH.

Figure 1: (a) H&E and Masson’s trichrome staining (magnification 200×). (b) Relative Ashcroft score. *P < 0.05 vs. control group.
Figure 2: ER stress and NLRP3 inflammasome activation increased in the alveolar region in the BLM group. (a–c) Immunochemical staining of ER stress markers Grp78, Grp94, and CHOP and (d–g) NLRP3 inflammasome-related proteins NLRP3, IL1β, ASC, and N-GSDMD.
2.12. Statistical Analysis. $T$-test was utilized to evaluate differences between groups and ANOVA to evaluate differences between more than two groups. $P < 0.05$ was considered as significant difference.

3. Results

3.1. Elevation of ER Stress and NLRP3 Inflammasome in the Mouse Model of BLM-Induced Pulmonary Fibrosis. BLM-induced pulmonary fibrosis in mice was detected by hematoxylin and eosin and Masson’s trichrome staining (Figure 1(a)). The fibrosis score was also increased in BLM-induced pulmonary in mice compared with control group (Figure 1(b)). Immunohistochemical staining (Figures 2(a)–2(c)) of ER stress markers in the alveolar region revealed decreased expression of Grp78 in the BLM model group, while expression of Grp94 and CHOP increased, suggesting that loss of the chaperone protein Grp78 promoted ER stress, which was consistent with previous reports [23]. Simultaneously, compared with the control group, elevated alveolar expression of the NLRP3 inflammasome-related protein NLRP3, IL-1β, ASC, and N-GSDMD was detected in the BLM model group.
Figure 4: Continued.
Collectively, these observations indicated elevations of ER stress and NLRP3 inflammasome activation in BLM-induced pulmonary fibrosis.

3.2. Coexpression of ER Stress Marker and NLRP3 Inflammasome-Related Proteins in Type II Alveolar Epithelial Cells in BLM-Induced Pulmonary Fibrosis. Double-staining showed that the expression of the ER stress marker CHOP and NLRP3 colocalized with surfactant protein C (SPC) in the BLM model group, indicating that ER stress and NLRP3 inflammasome activation were closely linked in type II AECs in BLM-induced pulmonary fibrosis (Figures 3(a) and 3(b)). This conclusion was further supported by the increased colocalization of CHOP and NLRP3 with IL-1β (Figures 3(c) and 3(d)).

3.3. Endoplasmic Reticulum Stress Promoted NLRP3 Inflammasome Activation and Pyroptosis in Type II Alveolar Epithelial Cells. To investigate whether ER stress induced-NLRP3 inflammasome activation in type II AECs, we stimulated A549 cell lines with tunicamycin (1 μg/mL) for 24 h. (a–e) Protein levels of the ER stress markers Grp94 and CHOP and the NLRP3 inflammasome-related proteins NLRP3, ASC, cleaved caspase-1, cleaved IL1β, and N-GSDMD were detected by Western blot analysis. (f, g) Colocalization of Grp94/NLRP3 and CHOP/NLRP3 was detected by immunofluorescence staining. (h) LDH release assay of cell viability. (i) Cell viability was assessed by CCK8 assay. *P < 0.05 vs. control group, **P < 0.05 vs. tunicamycin group, (j) LDH release assay of cell viability, (k) cell viability was assessed by CCK8 assay. n.s.: not significant vs. control group, *P < 0.05 vs. tunicamycin group.
increased compared with control group, and these changes were suppressed by 4PBA (Supplementary Figure 2). In addition, double immunofluorescence staining showed that the ER stress markers Grp94 and CHOP colocalized with NLRP3 in A549 cells simulated with tunicamycin, which further confirmed ER stress induced-NLRP3 inflammasome activation (Figures 4(f) and 4(g)). Furthermore, LDH release and CCK8 assays revealed that LDH release was increased while cell viability was decreased stimulated with tunicamycin compared with the control groups (Figures 4(h) and 4(i)). Indeed, after confirming siRNA-mediated knockdown of NLRP3 expression in A549 cells by Western blot and RT-qPCR analyses (Supplementary Figure 3), we showed that NLRP3 knockdown inhibited the release of LDH and decrease of cell viability stimulated by tunicamycin, indicating that ER stress promoted cell pyroptosis (Figures 4(j) and 4(k)).

3.3.1. Activation of the cAMP/PKA Pathway in BLM-Induced Pulmonary Fibrosis. Immunohistochemical staining revealed the expression of PKA elevated in the BLM model group compared with the control group (Figure 5(a)). Double immunofluorescence staining showed that colocalization of SPC with cAMP and PKA increased in the BLM model group (Figures 5(b) and 5(c)). Interestingly, colocalization of NLRP3 with cAMP also increased in the BLM model group, indicating a potential link between the cAMP/PKA pathway and the NLRP3 inflammasome in type II AECs in BLM-induced pulmonary fibrosis.

3.4. ER Stress Induced Upregulation of the cAMP/PKA Pathway in Type II AECs. Compared with the control group, intracellular cAMP levels and the expression of PKA protein were increased in the tunicamycin group (Figures 6(a) and 6(b)). Double immunofluorescence staining showed that the ER stress marker Grp94 colocalized with cAMP and NLRP3 colocalized with cAMP (Figures 6(c) and 6(d)). Collectively, these results indicated that ER stress induced activation of the cAMP/PKA pathway and that the cAMP/PKA pathway was closely associated with the NLRP3 inflammasome.

3.5. Inhibition of the cAMP/PKA Pathway Exacerbated Type II AEC Death Induced by ER Stress. We pretreated A549 cells with KH7 (adenylate cyclase inhibitor) and H89 (PKA inhibitor) before tunicamycin treatment. KH7 and H89 further increased the LDH release and decreased the cell viability induced by ER stress (Figures 7(a)–7(d)). In addition, we found that the adenylate activator forskolin reversed the
Figure 6: Continued.
release of LDH and decrease of cell viability induced by ER stress (Figures 7(e) and 7(f)). Forskolin attenuated the levels of NLRP3 and ASC induced by ER stress (Figure 7(g)). These results indicated that the cAMP/PKA pathway regulated ER stress-induced type II AEC pyroptosis via a negative feedback mechanism.

4. Discussion

Our current study confirmed the potential links among ER stress, NLRP3 inflammasome, and cAMP/PKA pathway in type II AECs in pulmonary fibrosis. We further demonstrated that ER stress induced-NLRP3 inflammasome activation upregulated cAMP/PKA pathway and pyroptosis in A549 cells. In addition, we found that inhibition of the cAMP/PKA pathway further promoted ER stress induced-pyroptosis. These findings indicated that ER stress promoted NLRP3 inflammasome activation and further facilitated pyroptosis in type II AECs which resulted to pulmonary fibrosis progression, and cAMP/PKA may act as a negative feedback regulator (Figure 8).

ER stress-induced apoptosis of type II AECs has been considered to be a crucial component of the mechanism of pulmonary fibrosis [1–3]. However, numerous research have found that ER stress could facilitate NLRP3 inflammasome activation by promoting upregulation of TXNIP [5, 6], accumulation of ROS [24], activation of NF-κB [25], potassium efflux [26], and calcium influx [27]. Thus, we suspected that there might be a similar mechanism in pulmonary fibrosis, such as ER stress facilitating AECs pyroptosis by promoting NLRP3 inflammasome. Compared with apoptosis, an immune-silent programmed death [28], pyroptosis could release IL1β and IL18 [29] which could interact with macrophages and fibroblast and therefore have more a strong effects on mechanism of pulmonary fibrosis.

The adenylate cyclase activator forskolin has been detected to alleviate the progression of pulmonary fibrosis [30]. Importantly, it has been reported that cAMP levels was decreased in lung fibroblasts in IPF due to repression of Gαs-coupled receptors [31–33]. Furthermore, many studies found that stimulation of the cAMP/PKA pathway suppressed NLRP3 inflammasome activation [15–20]. Interestingly, ER stress may promote cAMP/PKA pathway activation [21, 22]. Simultaneously, we also found that ER stress promoted cAMP/PKA pathway activation in type II AECs. Furthermore, cAMP/PKA pathway activation inhibited ER stress-induced NLRP3 inflammasome activation and cell pyroptosis, while inhibition of the cAMP/PKA pathway further exacerbated ER stress-induced cell death. Our observations indicated that upregulation of cAMP/PKA pathway may alleviate pulmonary fibrosis through inhibiting ER stress-induced NLRP3 inflammasome activation in type II AECs.

Our study has certain deficiencies, which needs to be further explored. A549 cell line is a neoplastic cell line, although several researches have used it as a type II AECs [34, 35]. In addition, it is unclear whether the upregulation of cAMP/PKA pathway could suppress BLM-induced pulmonary fibrosis through inhibiting ER stress-induced NLRP3 inflammasome activation of type II AECs. Furthermore, it is unknown the mechanism by which ER stress upregulates cAMP/PKA pathway.

In summary, our study initially confirmed ER stress-induced NLRP3 inflammasome activation in type II AECs, promoted cell pyroptosis, and ultimately exacerbated pulmonary fibrosis. Furthermore, we also indicated that cAMP/PKA may act as a negative feedback regulator of ER stress-induced NLRP3 inflammasome activation, thereby inhibiting type II AEC pyroptosis and eventually alleviating pulmonary fibrosis. These findings gave new insights into the mechanism of pulmonary fibrosis.
Figure 7: Continued.
**Data Availability**

The data used to support the findings of this study are included within the article.

**Conflicts of Interest**

The authors declare that they have no conflicts of interest.

**References**


27. S. Lee, G. Kim, N. Y. Kim, S. Kim, P. Ghosh, and D. Rhee, "ATF3 stimulates IL-17A by regulating intracellular Ca2+ /ROS-dependent IL-1β activation during Streptococcus pneumoniae infection," Frontiers in Immunology, vol. 9, 2018.


